ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0663

Disappearing Digits: A National Retrospective Matched Cohort Study Examining the Risk of Lower Extremity Amputation in Gout

Quint Soto1, Alison Petro1, Bryant England1, Harlan Sayles1, Lindsay Helget1, Punyasha Roul1, Tuhina Neogi2, James O'Dell1, Brian LaMoreaux3 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2Boston University School of Medicine, Boston, MA, 3Horizon Therapeutics plc, Deerfield, IL

Meeting: ACR Convergence 2021

Keywords: Comorbidity, gout, surgery

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Gout is associated with a number of comorbidities such as diabetes that are known risk factors for peripheral vascular disease. These comorbidities along with manifestations that mimic infection could place patients with gout at an increased risk of undergoing lower extremity amputation (LEA). The goal of this study was to determine if patients with gout are at a higher risk of undergoing LEA and to determine if this risk is independent of diabetes and other comorbidities.

Methods: We performed a retrospective matched cohort study using national Veterans Health Administrative (VHA) data from January 1999 to July 2015. Patients with gout were identified by the presence of ≥2 ICD9 codes (274.X). Gout patients were matched up to 1:10 by birth year, sex, and calendar year to patients without gout. Patients receiving LEA prior to the index date were excluded. LEA was defined using ICD9 procedure and common procedural terminology (CPT) codes and categorized as toe, transmetatarsal, below-the-knee, or above-the-knee. Diabetes and other comorbidities (e.g., peripheral vascular disease) were identified using ICD9 codes. Patients were followed until LEA or censoring due to death or end-of-study. Non-gout comparators developing gout later could “switch over”, contributing at-risk time for gout after matching to 10 new controls. Associations of gout with LEA were examined using multivariable Cox proportional hazards regression accounting for demographics, body mass index, and comorbidities. In secondary analyses, patients were examined in 4 groups based on the presence/absence of gout and diabetes.

Results: We identified 556,521 gout patients and 5,368,397 matched non-gout controls. Patients had a mean age of 67 years and were predominantly male (99%). There were 4,970 LEAs over 4.2 million pt-yrs of follow-up in patients with gout and 24,583 LEAs over 40 million patient-years of follow-up in controls. The risk of LEA (overall and by category) in patients with gout is shown in Figure 1. After accounting for covariates, gout was associated with a significant increase in LEA risk (HR 1.33; 95% CI 1.29-1.37). This risk was highest for below-the-knee amputations (HR 1.66; 95% CI 1.46-1.90). Of other risk factors, diabetes (HR 3.23; 95% CI 3.15-3.32) was most strongly associated with LEA. Results based on dual gout and diabetes statuses are shown in Figure 2. In the absence of diabetes, patients with gout demonstrated a 1.57-fold increased risk (95% CI 1.51-1.65) of LEA. The highest risk of LEA was among patients with gout and diabetes, exceeding the risk posed by diabetes alone.

Conclusion: Patients with gout are at a 33% increased risk for undergoing LEA, with an even higher risk for below-the-knee amputations. This risk is independent of other comorbidities that have been associated with LEA including diabetes. Further research is needed to better understand the surgical indications for these procedures, whether tophi (which can mimic osteomyelitis) are associated with heightened risk, and to what degree LEA might be prevented in this patient population through enhanced diagnostics or improved gout management.


Disclosures: Q. Soto, None; A. Petro, None; B. England, Boehringer-Ingelheim, 2; H. Sayles, None; L. Helget, None; P. Roul, None; T. Neogi, Pfizer/Lilly, 2, Regeneron, 2, Novartis, 2; J. O'Dell, None; B. LaMoreaux, Horizon Therapeutics plc, 3, 11; T. Mikuls, Gilead Sciences, 2, Horizon, 2, 5, Pfizer Inc, 2, Sanofi, 2, Bristol-Myers Squibb, 2.

To cite this abstract in AMA style:

Soto Q, Petro A, England B, Sayles H, Helget L, Roul P, Neogi T, O'Dell J, LaMoreaux B, Mikuls T. Disappearing Digits: A National Retrospective Matched Cohort Study Examining the Risk of Lower Extremity Amputation in Gout [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/disappearing-digits-a-national-retrospective-matched-cohort-study-examining-the-risk-of-lower-extremity-amputation-in-gout/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disappearing-digits-a-national-retrospective-matched-cohort-study-examining-the-risk-of-lower-extremity-amputation-in-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology